Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and pazopanib

moxifloxacin has been researched along with pazopanib in 2 studies

Compound Research Comparison

Studies
(moxifloxacin)		Trials
(moxifloxacin)		Recent Studies (post-2010)
(moxifloxacin)		Studies
(pazopanib)		Trials
(pazopanib)		Recent Studies (post-2010) (pazopanib)
3,1575521,6901,1472371,028

Protein Interaction Comparison

ProteinTaxonomymoxifloxacin (IC50)pazopanib (IC50)
Multidrug resistance-associated protein 4Homo sapiens (human)8.1
Tyrosine-protein kinase ABL1Homo sapiens (human)2.2043
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.21
Cytochrome P450 3A4Homo sapiens (human)0.03
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0837
Cytochrome P450 2D6Homo sapiens (human)0.03
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.0887
Fibroblast growth factor receptor 1Homo sapiens (human)0.1477
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.071
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.032
Fibroblast growth factor receptor 2Homo sapiens (human)0.14
AcetylcholinesteraseHomo sapiens (human)0.93
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.0467
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.4929
Receptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)0.873
Discoidin domain-containing receptor 2Homo sapiens (human)0.0505
Receptor protein-tyrosine kinase Homo sapiens (human)2.2043

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Ball, HA; Dar, MM; Heath, EI; Infante, J; Kasubhai, S; Kleha, JF; Lewis, LD; LoRusso, P; Luu, T; Ma, B; Stephenson, J; Suttle, AB; Tan, AR1

Reviews

1 review(s) available for moxifloxacin and pazopanib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for moxifloxacin and pazopanib

ArticleYear
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:3

    Topics: Adult; Aged; Algorithms; Angiogenesis Inhibitors; Anti-Bacterial Agents; Aza Compounds; Blood Pressure; Confidence Intervals; Double-Blind Method; Electrocardiography, Ambulatory; Female; Fluoroquinolones; Heart Conduction System; Heart Rate; Humans; Indazoles; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Neoplasms; Pyrimidines; Quinolines; Sulfonamides; Young Adult

2013